Can an arthritis drug ease pain in rare MPS diseases?
NCT ID NCT03153319
First seen Feb 02, 2026 · Last updated May 13, 2026 · Updated 7 times
Summary
This study tests whether adalimumab, a drug used for arthritis, can reduce pain and improve joint movement in people with MPS I, II, or VI. It includes 14 children and adults who have significant pain and limited joint motion. Participants receive either adalimumab or a placebo for 16 weeks, then all can receive the drug for up to a year.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MUCOPOLYSACCHARIDOSIS II are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Lundquist Institute at Harbor-UCLA Medical Center
Torrance, California, 90502, United States
Conditions
Explore the condition pages connected to this study.